
Invex
IXC.AXInvex Therapeutics Ltd Price (IXC.AX)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
75,312,339
(0.2109)%
Community Sentiment
0 votes
↑ 0%
↓ 0%
Description
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia. Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $0.059-0.09
- Market Cap 5.26M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Ms. Narelle Warren B.Com, B.Com., L.L.B., LLB
- IPO Date: July, 05, 2019
- Country: AU
- Currency: AUD
- Headquaters: Perth, WA
- Employees: No Data
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
